For those born with certain types of congenital deafness, the cochlear implant has been a positive and enabling technology.

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

Four decades have passed since cochlear implants gave infants born deaf the ability to hear. Now, gene therapy promises to restore natural hearing for those born with a rare form of deafness, and the ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol and triglycerides in people with difficult-to-treat lipid disorders, ...

This is the first time such results have been achieved in both children and adult patients born with a specific type of congenital deafness. When you purchase through links on our site, we may earn an ...

Qure has previously announced that it held a Type A meeting with the U.S. Food and Drug Administration to discuss the ...

Live Science's health channel editor makes predictions about the medical breakthroughs and public health shifts to come in 2026.

This sponsored article was provided by a partner and is not editorial content from Los Angeles Magazine or the Engine Vision Media Network. Every cell in your body holds a unique genetic code within ...

Two of Opus's seven gene therapy assets are in clinical trials, with additional programs expected to enter the clinic.

Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that results from mutations in the DMD gene. Gene therapies for DMD change genetic material in a person’s body to treat this condition.